Research programme: skin disorders therapies - Acrux/Napa Biosciences
Latest Information Update: 11 Mar 2006
At a glance
- Originator Acrux
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 23 May 2005 Preclinical trials in Skin disorders in Australia (Topical)
- 23 May 2005 Preclinical trials in Skin disorders in USA (Topical)